Business Description
Gossamer Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US38341P1021
Total Employee Number:
162Description
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 | |||||
Equity-to-Asset | -1.22 | |||||
Debt-to-Equity | -0.43 | |||||
Debt-to-EBITDA | -0.35 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -31.75 | |||||
Beneish M-Score | -1.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.7 | |||||
3-Year EPS without NRI Growth Rate | 35.8 | |||||
3-Year FCF Growth Rate | 30.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 83.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 23.26 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.98 | |||||
9-Day RSI | 33.41 | |||||
14-Day RSI | 39.21 | |||||
3-1 Month Momentum % | 5.41 | |||||
6-1 Month Momentum % | -63.29 | |||||
12-1 Month Momentum % | -94.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.53 | |||||
Quick Ratio | 0.53 | |||||
Cash Ratio | 0.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.3 | |||||
Shareholder Yield % | 62.93 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -297.67 | |||||
Net Margin % | -235 | |||||
EBITDA Margin % | -212.85 | |||||
FCF Margin % | -305.25 | |||||
OCF Margin % | -305.25 | |||||
ROA % | -75.64 | |||||
ROIC % | -302.15 | |||||
3-Year ROIIC % | -2825.76 | |||||
ROC (Joel Greenblatt) % | -2730.08 | |||||
ROCE % | -125.85 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.61 | |||||
EV-to-EBIT | -0.42 | |||||
EV-to-EBITDA | -0.42 | |||||
EV-to-Forward-EBITDA | -0.35 | |||||
EV-to-Revenue | 0.9 | |||||
EV-to-Forward-Revenue | 2.12 | |||||
EV-to-FCF | -0.29 | |||||
Earnings Yield (Greenblatt) % | -238.1 | |||||
FCF Yield % | -250.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gossamer Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 45.795 | ||
| EPS (TTM) (€) | -48.056 | ||
| Beta | 2.112 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 103.01 | ||
| 14-Day RSI | 39.21 | ||
| 14-Day ATR (€) | 1.269568 | ||
| 20-Day SMA (€) | 11.224 | ||
| 12-1 Month Momentum % | -94.02 | ||
| 52-Week Range (€) | 8.64 - 256.64 | ||
| Shares Outstanding (Mil) | 6.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gossamer Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gossamer Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 53 days | ||
| 0.0125:1 Stock Split | 2026-09-11 | 9.68 (-7.28%) | ||
| Cantor Global Healthcare Conference | 2026-09-09 10:55 | 12.08 (-1.95%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 12.08 (-1.63%) | ||
| General meeting for 2026 | 2026-06-04 09:00 | 12.88 (-6.67%) | ||
| First quarter earnings conference call for 2026 | 2026-05-18 08:00 | 22.72 (+3.27%) | ||
| First quarter earnings results for 2026 | 2026-05-18 | 22.72 (+3.27%) | ||
| Annual report for 2025 | 2026-03-17 | 31.36 (+1.77%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 31.36 (+1.77%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 159.44 (-2.88%) |
Show
Entries
Gossamer Bio Inc Frequently Asked Questions
What is Gossamer Bio Inc(STU:4GB0)'s stock price today?
The current price of STU:4GB0 is €9.68. The 52 week high of STU:4GB0 is €256.64 and 52 week low is €8.64.
When is next earnings date of Gossamer Bio Inc(STU:4GB0)?
The next earnings date of Gossamer Bio Inc(STU:4GB0) is 2026-11-05 Est..
Does Gossamer Bio Inc(STU:4GB0) pay dividends? If so, how much?
Gossamer Bio Inc(STU:4GB0) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers